PPARG and metabolic dysfunction-associated steatohepatitis: Later, Cusi and colleagues demonstrated in clinical trials of the PPARγ activator pioglitazone that adiponectin elevation is the best predictor of histologic response in NASH and fibrosis (256, 257).